title: More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
abstract: BACKGROUND
  During maintenance proton pump inhibitor (PPI) therapy, patients with gastroesophageal reflux disease (GERD) sometimes complain of upper gastrointestinal symptoms.
  
  
  OBJECTIVE
  To evaluate upper gastrointestinal symptoms in patients on maintenance PPI therapy for erosive GERD or non-erosive reflux disease (NERD) without endoscopic mucosal breaks by using a new questionnaire.
  
  
  METHODS
  At Gunma University Hospital over a 12-month period during 2011-2012, we enrolled 30 consecutive patients with erosive GERD and 46 patients with NERD. All patients had been on maintenance PPI therapy for more than 1 year. We used the modified frequency scale for the symptoms of GERD (mFSSG) questionnaire to assess upper gastrointestinal symptoms. We also asked patients about their satisfaction with maintenance therapy and whether they wished to change their current PPI.
  
  
  RESULTS
  The NERD patients had significantly higher symptom scores than the erosive GERD patients. There was no difference in the treatment satisfaction rate between patients with erosive GERD and NERD, but more patients with NERD wanted to change their PPI therapy. There was no difference in the mFSSG score between NERD patients who wished to change their current PPI therapy and those who were satisfied with it.
  
  
  CONCLUSIONS
  During maintenance PPI therapy, upper gastrointestinal symptoms were more severe in NERD patients than in patients with erosive GERD. NERD patients often wished to change their PPI therapy, but this was not dependent on the severity of their upper GI symptoms.
authors.affiliation: Department of Gastroenterology, Gunma University Hospital, Maebashi, Gunma, Japan, mkusano@gunma-u.ac.jp.
authors.forename: Motoyasu
authors.initials: M
authors.lastname: Kusano
authors.forename: Hiroko
authors.initials: H
authors.lastname: Hosaka
authors.forename: Osamu
authors.initials: O
authors.lastname: Kawamura
authors.forename: Akiyo
authors.initials: A
authors.lastname: Kawada
authors.forename: Shiko
authors.initials: S
authors.lastname: Kuribayashi
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Shimoyama
authors.forename: Hidetoshi
authors.initials: H
authors.lastname: Yasuoka
authors.forename: Masafumi
authors.initials: M
authors.lastname: Mizuide
authors.forename: Taku
authors.initials: T
authors.lastname: Tomizawa
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Sagawa
authors.forename: Ken
authors.initials: K
authors.lastname: Sato
authors.forename: Masanobu
authors.initials: M
authors.lastname: Yamada
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004334:Drug Administration Schedule; D057915:Drug Substitution; D004415:Dyspepsia / Q000209:etiology; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000209:etiology; D004945:Esophagoscopy / Q000379:methods; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D054328:Proton Pump Inhibitors